Stamatatos Leonidas, Pancera Marie, McGuire Andrew T
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Department of Global Health, University of Washington, Seattle, WA, USA.
Immunol Rev. 2017 Jan;275(1):203-216. doi: 10.1111/imr.12483.
In 2009, Dimitrov's group reported that the inferred germline (iGL) forms of several HIV-1 broadly neutralizing antibodies (bNAbs) did not display measurable binding to a recombinant gp140 Env protein (derived from the dual-tropic 89.6 virus), which was efficiently recognized by the mature (somatically mutated) antibodies. At that time, a small number of bNAbs were available, but in the following years, the implementation of high-throughput B-cell isolation and sequencing assays and of screening methodologies facilitated the isolation of greater numbers of bNAbs from infected subjects. Using these newest bNAbs, and a wide range of diverse recombinant Envs, we and others confirmed the observations made by Dimitrov's group. The results from these studies created a paradigm shift in our collective thinking as to why recombinant Envs are ineffective in eliciting bNAbs and has led to the "germline-targeting" immunization approach. Here we discuss this approach in detail: what has been done so far, the advantages and limitations of the current germline-targeting immunogens and of the animal models used to test them, and we conclude with a few thoughts about future directions in this area of research.
Immunol Rev. 2017-1
Curr Opin HIV AIDS. 2023-11-1
Proc Natl Acad Sci U S A. 2025-8-19
Nat Rev Microbiol. 2025-7-23
J Int AIDS Soc. 2025-5
Vaccines (Basel). 2025-1-31
Clin Transl Immunology. 2016-7-22
Sci Transl Med. 2016-4-27
Sci Transl Med. 2015-12-23